Pharma communicators keep eye on FDA after it singles out product pitch
WASHINGTON: Healthcare communicators are concerned that a Food and Drug Administration letter criticizing a pharmaceutical company's PR pitch may change the way agencies and their pharma clients promote products.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>